Shots:

• The P-III study evaluates TX05 (biosimilar- trastuzumab) vs Herceptin in 809 patients with HER2-positive early-stage breast cancer
• The results showed that the proportions of patients that meet pCR criteria for equivalence were highly similar b/w TX05 (48.8%) and TRA (45.3%) cohorts; ORR (84.3%) & (85.0%); CR; PR and stable disease were also highly similar- patients experienced TEAEs (62.4% vs 62.5%)- respectively
• Additionally- the therapy was well tolerated & the safety profile was consistent with the known profile of TRA

  | Ref: Centre for Biosimilar | Image: Tanvex Biopharma